5-BROMO-2-FLUORO-3-(TRIFLUOROMETHYL)BENZOIC ACID, 95%, 100mg

2,3-Dihydro-1,4-benzodioxin-5-amine, 97.0%, 1g

2-(2-Aminoethylamino)ethanol, min 98%, for synthesis, 1 L, glass packaging

GC capillary column ROTI®Cap-1, 25 m, 0.20 mm, 0.35 µm, 1 Piece(s)

(2,3-Dihydro-benzo[1,4]dioxin-5-yl)-methanol, 95.0%, 250mg

1-(benzenesulfonyl)-4-chloro-3-iodo-1H-pyrrolo[2,3-b]pyridine, 5g

Tert-butyl (R)-1-(chloromethyl)-5-hydroxy-1,2-dihydro-3H-benzo[e]indole-3-carboxylate, 97%, 1g

7-AMINO-3,4-DIHYDRO-1,4-BENZOXAZEPIN-5(2H)-ONE, 95.0%, 2g

5-(TRIFLUOROMETHYL)-1,3,4-THIADIAZOL-2(3H)-ONE, 95.0%, 250mg

(2S,4S)-Fmoc-4-azido-pyrrolidine-2-carboxylic acid, 99.0%, 1g

5-Chlorosalicylidene Aniline, 1g

N-(2,6-Dimethylphenyl)-2-(2-oxopyrrolidin-1-yl)acetamide, 95.0%, 1g

3-{[(4-fluorophenyl)methyl]amino}benzamide, 95.0%, 250mg